News & Events - TVM Capital Life Science Venture Capital

Get the latest information on TVM and its portfolio companies.

We hope to see you at an upcoming event.

Get the latest information on TVM and its portfolio companies.

Events

All Events

September 16-20, 2024

LSI Europe ‘24

Emerging Medtech Summit 2024 – Life Science Intelligence

Sintra, Portugal

Website

September 25-26, 2024

24th Annual Biotech in Europe Forum

TVM Capital Life Science will take part in the 24th Annual Biotech in Europe Forum September 25-26, 2024 in Basel, Switzerland at the Mövenpick Hotel.

Get the latest information on TVM and its portfolio companies.

Events

LSI Europe ‘24

24th Annual Biotech in Europe Forum

BIO-Europe 2024

News

Discover the Power of AI in Biopharma: TVM to Host Thought-Provoking Sessions at Bio-Europe 2024

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

TVM Capital Life Science to Participate in LSI Europe ’24 Emerging Medtech Summit 2024

CSA Medical Raises $53 Million in Series D Financing to Support PMA of the RejuvenAir System

Access Vascular Announces Strategic Partnership with Capstone Health Alliance

Leon-Nanodrugs Secures Funds in a Series D Financing

Access Vascular Prepares Catheter Location Technology for FDA Submission

Kent Imaging Announces FDA Clearance of SnapshotNIR KD205

TVM Capital Life Science Leads €23 Million Series C Financing Round for Medical Reporting Technology Pioneer, Smart Reporting

Kent Imaging and WoundCentrics Propel Wound Care Forward with New Partnership

TVM Capital Life Science to Participate in LSI USA ’24 Emerging MedTech Summit 2024

TVM Capital Life Science Co-Leads $16 Million Series A Financing Round for Vektor Medical to Revolutionize Arrhythmia Care

TVM Capital Life Science Announces €8 Million Investment in myo to Revolutionize Elderly Care via Innovative, Easy-to-Use App

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

TVM Capital Life Science to participate in LSI USA ’23 Emerging Medtech Summit 2023

TVM Capital Life Science Announces Promotions to Recognize Significant Contributions of Up-and-Coming Leaders

Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ

TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc.

Panthera D-SAD Classic oral appliance now eligible for Medicare reimbursement

Kent Imaging Recognized as Most Innovative Medical Imaging Technology Developer in Canada

Egg Medical, Inc., Closes on $13 million Financing

CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO

CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan

CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer

Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies

TVM Capital Life Science promotes Dr. Sascha Berger and Dr. Alain Thibault to General Partner

Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

Nekonal and TVM Capital Life Science Announce Creation of T7 Therapeutics to Develop Innovative Therapy for Patients with Auto-immune diseases

Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

Rapid Micro Biosystems Announces Pricing of Initial Public Offering

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021Following Pre-NDA Meeting with FDA

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

Access Vascular, Inc. Secures $20 Million in Series B Financing

TVM Life Science Innovation II SCSp Announces Investment in Vespina Lifesciences Inc.

TVM Life Science Innovation II SCSp Announces Investment in Sarkana Pharma, Inc.

Kent Imaging Becomes Net Health’s First Integrated Imaging Device

TVM Life Science Innovation II SCSp Announces Investment in ImmunoRx Pharma, Inc.

Kent Imaging Inc. is accelerating its growth through a US$15M investment by TVM Life Science Innovation II SCSp

Dentsply Sirona and Panthera Dental announce collaboration: fully digital workflow for custom-made sleep devices

TVM Capital Life Science Announces Substantially Oversubscribed US$478 Million Final Closing of TVM Life Science Innovation II, largest fund in the firm’s history

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021
Following Pre-NDA Meeting with FDA